Antipodes Partners awarded

2026 Fund Manager of the Year, Australia

Morningstar Awards 2026 © Morningstar, Inc. All Rights Reserved.

In the Spotlight with Lonsec

In global equities, everyone sees the same companies – but not everyone sees the same opportunities. The difference lies in research depth, organisational design, and the discipline to pay the right price.

Jacob Mitchell recently joined Lonsec’s Hong Hon for an ‘In the Spotlight’ interview, unpacking how our specialist teams generate high-conviction ideas across global supply chains – and why getting the price right is just as important as picking the right company.

My Webpage

Transcript

Welcome to In the Spotlight. My name is Hong Hon, Manager of Global Equities at Lonsec Research and Ratings. Today, I’m joined by Jacob Mitchell, CIO of Global Equities and founder of Antipodes Partners. Jacob founded the business in twenty fifteen after spending fourteen years at Platinum Asset Management. Jacob is based in Sydney. Thanks for joining us today, Jacob.

Yeah, it’s great to be here, Hon. And looks like we both have the same wardrobe consultant.

So, Jacob, before we jump into the discussion, are you able to give us a bit of background around the Antipodes business as of today and also the need that Antipodes is trying to address within clients’ portfolios?

Yeah. Sure. So, look, over the past ten years, we started our life as a global equity specialist offering three strategies, our global long value fund, our global long short fund, and an Asia fund. And over that time we’ve had great success in in those strategies and ultimately in both Australian retail, also with institutions, and offshore with offshore investors. About eighteen months ago, we added to our stable the Maple Brown Abbott via acquisition, the MBA business, a very storied boutique, one of the original Australian boutiques. And so that means we’re now across the group. We have five investment teams.

The good news is I’m only responsible for one of them, the global equities team. The other four report up to the CEO of the Antipodes Group, Andrew Findlay. It’s very pleasing that across all teams we’re seeing really good risk adjusted returns, which is certainly what we set out to do in the global equities team. Really, alpha but with a real emphasis on generating return relative to good downside protection and ultimately a value bias. Ultimately pragmatic value is that philosophy is about paying the right price relative to the characteristics of the business growth and business resilience but yet paying the right price across those characteristics.

Jacob, you mentioned value orientated down price protection characteristics that many managers within your peer group also say they are looking to achieve. But what makes Antipodes investment approach distinctive from some of those peers?

Yeah, look, Hon, as you can appreciate, global equities is a very broad benchmark in terms of ACWI – The All World Countries World Index –񞏷is very broad by a number of companies. So we really lead with industry research to sort of win those longer term insights on what drives competitive advantage in that industry and then map that to the winners and the losers at the company level. And that we’re a team of thirty. That allows us to get across the universe of opportunities in a really efficient way, and we’re ready to act when those industries and those individual companies are falling out of favour and we think the market’s getting it wrong. So, that’s number one. It’s an industry led approach.

Number two, I think it’s the way we structure the team. We don’t have too many silos. We really have five coverage teams plus a quant macro team to cover the universe, and we really incentivise each of the teams within the teams to work in a really collaborative manner to hunt down those pragmatic value opportunities. Those teams are running best idea long short portfolios, which are the building blocks for all the strategies, for the large cap strategies plus the SMID cap strategies. And because we’re doing the combination of those two things, industry led and then a very collaborative approach, we’re finding opportunities up and down the market cap spectrum. If you understand the industry supply chain, you’ll understand opportunities in the large caps and the SMID caps.

And then finally quant macro, it’s bottom up and top down working together. We think over time, we’ve evolved our quant process to ultimately incorporate not just screening for opportunities but risk modelling of the aggregate portfolio risk, making sure if we’re building in tilts through the stock picking that we’re being compensated for that risk, and also being able to optimise portfolios, run scenario analysis to see how the portfolio is going to behave on a forward looking basis relative to our macroeconomic outlook.

And then I think more recently also starting to think about more systematic quant to look for alpha opportunities, not just measure risk but to look for alpha opportunities and use those to build, for example, in long short portfolios, baskets targeting a particular characteristic very diversified baskets where you can back test the outcome. So, it’s been a journey for us incorporating quant with our bottom up stock picking. But obviously as your technology has evolved we’ve evolved along with that. We’ve evolved our toolkit. So, that would be the third aspect. And all three of them I think, it’s industry led, it’s our organisational design, and it’s the combination of top down and bottom up working together. that’s how I would state our competitive advantage.

So within the strategies that you manage, how do you balance between the two, the alpha generation aspect . Along with some of the risk management aspects that you’ve mentioned, specifically around factor exposures and foreign currencies?

Yeah, it’s a good question. So in the portfolios, we’ll always think about at the currency level how much currency exposure to any individual currency are we building in through the stock picking.

So that’s not just the obvious, like, do you a stock that’s a Japanese stock so you’re taking on yen exposure? But also the sensitivity of that company to the yen, if it’s an exporter, it may be negative correlated to an appreciating yen, so things like that. So we look at the tilts at an aggregate level relative to the benchmark, the benchmark weight of that currency.

And if we think, we’ve built in, as we had recently where we’ve a big overweight in Europe, and that hasn’t been driven by being very constructive on the European economy, we’ve been buying multinationals in Europe. So we’ve ended up with a lot of Euro exposure. And we actually didn’t think the Euro was particularly timely, and so we ended up very overweight with Euro, and we decided to hedge out some of that exposure.

So, we have a currency overlay where we’re trying to number one manage risk but also hedge that into a cheaper currency where we potentially can also drive some return.

Moving from currency to factor exposures, pragmatic value will always end up with some tilt to value. When value as a factor is cheap, you’d expect that, as it is today, you’d expect that tilt to be higher than in a market where factors were more arguably fairly priced as we’ve seen.

If you go back to post the GFC, the market wasn’t really paying a huge difference between a quality company, a growth company, and a classic value stock. There was a lot more convergence. Today, there’s a lot more extreme. They have a more extreme tilt to value. It’s a question of what’s coming with that tilt. Often advisers have the experience with value managers of a very cyclical episodic return outcome because low multiple sometimes means also very cyclical.

I think we’ve proven through our record that you can build a portfolio with a value tilt and not over expose investors to cyclicality and provide a more consistent return and certainly a good return relative to volatility. I mean, all over all periods the volatility of our funds is lower than the benchmark and yet we’re generating returns ahead of benchmark.

So, Jacob, you mentioned earlier that you run large cap and small cap portfolios. What other strategies does Antipodes offer?

Yeah, sure. So, have in large cap, we have the Antipodes Global Value Fund, which is also available in ETF form on the ASX as AGX1. The Antipodes Global Fund, which is our variable beta, long short offering, which has delivered from inception a Sharpe ratio. Now, Sharpe being how much return you’re getting per unit of volatility of about one point two versus the benchmark at about zero point nine. And very good downside protection, i.e that fund has typically had been protecting from inception has protected investors from roughly seventy percent of downside end markets.

And we think that’s very appropriate for the environment we’re in where you’ve got a very mature bull market, valuations are stretched, the benchmark’s very concentrated, and you tend to get late cycle these tail risks building beneath the surface and that’s when you need to have a variable beta in your toolkit, especially if you’re a pension phase style investor where the opportunity cost of that drawdown is going to be really, really high.

So, that’s really pension phase. If you think about accumulation phase, it’s really the long, the Antipodes Global Value Fund, and then coming up just over three years of track record in our SMID fund. Long only once again, also available on the ASX as ticker MIDS. The performance of that fund has been anything but mid. It’s really category leading performance. And I think that fund, it’s a very different the SMID benchmark doesn’t have the problem of the ACWI benchmark where it doesn’t have that high level of concentration. We don’t think it’s as efficiently covered and we certainly think that strategy is really just competing as a category fund, just a fund that you can use in your SMID allocation.

As I said before, really built off that industry led approach which allows us to understand the supply chain and then invest across the market cap spectrum. We also offer a number of EM related funds, EM long only, Asia long only, and a China long only as well. And, yeah, we’re definitely excited about the prospects for those regions, you know, in a in a world which has celebrated US exceptionalism. We think those regions offer a lot of opportunity.

Subscribe to receive the latest news and insights from the Antipodes team

IMPORTANT INFORMATION:

All content in respect of the Antipodes Global Shares (Quoted Managed Fund) (ARSN 625 560 269), the Antipodes Global Fund – Long (ARSN 118 075 764), the Antipodes Global Fund (ARSN 087 719 515), and the Antipodes Emerging Markets (Managed Fund) (ARSN 096 451 393) is issued by Pinnacle Fund Services Limited ABN 29 082 494 371 AFSL 238 371 (“PFSL”) as responsible entity of the Funds and is prepared by Antipodes Partners Limited (ABN 29 602 042 035) (AFSL 481580) (“Antipodes”) as the investment manager of the Trust. PFSL is not licensed to provide financial product advice.
The information provided is of a general nature only and has been prepared without taking into account your objectives, financial situation or needs. Before making an investment decision in respect of the Funds, you should consider the current Product Disclosure Statement (‘PDS’) and Target Market Determination (‘TMD’) of the Funds and the Fund’s other periodic and continuous disclosure announcements lodged with the ASX, which are available at www.asx.com.au, and assess whether the Fund is appropriate given your objectives, financial situation or needs. If you require advice that takes into account your personal circumstances, you should consult a licensed or authorised financial adviser. The Product Disclosure Statement (‘PDS’) and Target Market Determination (‘TMD’) of the relevant Fund are available via below links. Any potential investor should consider the PDS and TMD before deciding whether to acquire, or continue to hold units in, the Fund.
Links to Product Disclosure Statement: IOF0045AU, WHT0057AU, IOF0203AU, WHT3997AU
Links to Target Market Determination: IOF0045AU, WHT0057AU, IOF0203AU, WHT3997AU
For historic TMD’s please contact Pinnacle client service Phone 1300 010 311 or Email service@pinnacleinvestment.com
Neither PFSL nor Antipodes guarantees repayment of capital or any particular rate of return from the Funds. Neither PFSL nor Antipodes gives any representation or warranty as to the currency, reliability, completeness or accuracy of the information contained in this content. All opinions and estimates included in this website constitute judgments of Antipodes as at the date of website creation and are subject to change without notice. Past performance is not a reliable indicator of future performance. Stock commentary is illustrative only, it should not be considered as a recommendation to buy, hold, or sell any security. 

Share:

More Posts

Now available on the ASX: the Antipodes Global SMID Active ETF (ASX:MIDS)

X